DHC in the News

Finding closure: Lowering the costs of cell and gene therapies

by Dan Stanton Fully closed and automated platforms are key to reducing the current high costs of cell and gene therapy manufacturing, say industry experts. Cell and gene therapies (CGTs) have come a long way over the past two years, resulting in two chimeric antigen receptor (CAR) T-cell therapies – Kymriah and Yescarta – and the

Go to Article»

TrakCel Brings in New Director

Cardiff-headquartered TrakCel, which develops software for cell and gene therapy companies, has appointed a new director.

Dr. Anthony Davies, from Dark Horse Consulting, has been recruited as a non-executive director.

Go to Article»

CellGenix Appoints Leading Experts to Scientific Advisory Board

CellGenix, a global leader in providing GMP-grade raw materials for cell and gene therapy and tissue-engineered products, today announced the appointment of highly experienced and internationally respected experts in the field of cell and gene therapy to its Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to CellGenix as it continues

Go to Article»